Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance and Healthcare Utilization in Patients with Inflammatory Bowel Disease

被引：0
|
作者：
Sumedha V. Chablani
Claudia Ramos-Rivers
David G. Binion
Eva Szigethy
机构：
[1] UPMC Montefiore Hospital,Department of Medicine
[2] UPMC Presbyterian Hospital M2,Division of Gastroenterology, Hepatology and Nutrition
[3] Visceral Inflammation and Pain (VIP) Center,Division of Gastroenterology, Hepatology and Nutrition
来源：
Digestive Diseases and Sciences | 2018年 / 63卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2482 / 2484
页数：2
相关论文
共 50 条
  • [41] Benefits and Risks of Combining Anti-tumor Necrosis Factor with Immunomodulator Therapy in Pediatric Inflammatory Bowel Disease
    Cozijnsen, Martinus A.
    Escher, Johanna C.
    Griffiths, Anne
    Turner, Dan
    de Ridder, Lissy
    INFLAMMATORY BOWEL DISEASES, 2015, 21 (04) : 951 - 961
  • [42] Anti-Tumor Necrosis Factor Therapy and the Risk of Gestational Diabetes in Pregnant Women With Inflammatory Bowel Disease
    Cho, Yongtai
    Choi, Eun-Young
    Choi, Ahhyung
    Han, Jung Yeol
    Ye, Byong Duk
    Kim, Ju Hwan
    Shin, Ju-Young
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2025, 120 (01): : 241 - 250
  • [43] Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease Reply
    Bouguen, Guillaume
    Brunet, Tanguy
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (04) : 855 - 856
  • [44] Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
    Nawaz, Ahmad
    Glick, Laura R.
    Chaar, Abdelkader
    Li, Darrick K.
    Gaidos, Jill K. J.
    Proctor, Deborah D.
    Al-Bawardy, Badr
    ANNALS OF GASTROENTEROLOGY, 2023, 36 (01): : 39 - +
  • [45] Anti-Tumor Necrosis Factor Therapy and Risk of Kidney Function Decline and Mortality in Inflammatory Bowel Disease
    Sumida, Keiichi
    Shrestha, Prabin
    Mallisetty, Yamini
    Thomas, Fridtjof
    Gyamlani, Geeta
    Streja, Elani
    Kalantar-Zadeh, Kamyar
    Kovesdy, Csaba P.
    JAMA NETWORK OPEN, 2024, 7 (04) : E246822
  • [46] Ten-year outcomes of anti-tumor necrosis factor therapy in inpatients with inflammatory bowel disease
    Tai, J. E.
    Pavli, P.
    Subramaniam, K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 148 - 148
  • [47] Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy
    Ramos, J. M.
    Garcia-Sepulcre, M. F.
    Masia, M.
    Brotons, A.
    Grau, M. C.
    Gutierrez, F.
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2010, 102 (10) : 614 - U62
  • [48] Cutaneous manifestations of anti-tumor necrosis factor (anti-TNF) therapy in patients with inflammatory bowel disease (IBD): A case series
    Peer, F. C.
    Subramaniam, K.
    Pavli, P.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 108 - 108
  • [49] Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
    Pagnini, Cristiano
    Pizarro, Theresa T.
    Cominelli, Fabio
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [50] Characterization of Anti-Tumor Necrosis Factor Agent-Induced Lupus in Patients With Inflammatory Bowel Disease
    Murdoch, Travis B.
    Stinton, Laura
    Panaccione, Remo
    Kaplan, Gilaad
    Ghosh, Subrata
    Anderson, Carl A.
    Eksteen, Bertus
    GASTROENTEROLOGY, 2014, 146 (05) : S585 - S585
12345